ZSCAN5B Inhibitors
The chemical class termed ZSCAN5B inhibitors comprises a diverse array of compounds meticulously selected to modulate the expression of ZSCAN5B. Among these, Rigosertib stands out as a potent inhibitor directly targeting the PI3K/Akt pathway. This inhibition occurs at the molecular level, disrupting the intricate balance of signaling cascades and leading to the downregulation of ZSCAN5B. The interplay between PI3K/Akt and ZSCAN5B is a crucial aspect of cellular regulation, making Rigosertib a precise modulator of this protein. Another notable member of this chemical class is Selumetinib, a MEK inhibitor that exerts control over the MAPK pathway. Through the precise targeting of MEK, Selumetinib influences the phosphorylation cascade within the MAPK pathway, subsequently modulating ZSCAN5B expression. The indirect nature of this inhibition highlights the intricacies of cellular signaling networks and emphasizes the importance of specific pathway targeting in achieving the desired modulation of ZSCAN5B.
Sotrastaurin, a PKC inhibitor, adds another dimension to this class by disrupting the NF-κB pathway. The downstream effector ZSCAN5B is intricately linked to NF-κB signaling, and Sotrastaurin's selective interference with PKC ensures a targeted impact on this pathway. Consequently, ZSCAN5B modulation occurs as a result of the precise control exerted by Sotrastaurin over the NF-κB pathway. In summary, the ZSCAN5B inhibitors chemical class represents a strategic selection of compounds targeting key cellular pathways intricately linked to ZSCAN5B regulation. Each chemical within this class exerts its influence through precise and selective modulation of specific signaling cascades, showcasing the intricacies of cellular communication and providing valuable tools for the scientific exploration of ZSCAN5B function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
Selumetinib is a MEK inhibitor disrupting the MAPK pathway. ZSCAN5B, downstream of MAPK, is modulated as Selumetinib alters the phosphorylation cascade within the pathway. This compound exerts indirect control over ZSCAN5B through its specific inhibition of the MAPK signaling route. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib, a MEK inhibitor, attenuates the MAPK pathway. Through MAPK modulation, ZSCAN5B expression is influenced. Trametinib's impact on the MAPK pathway triggers downstream alterations, intricately linked to ZSCAN5B. Its specificity in targeting MEK ensures selective modulation of this pathway. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib inhibits Src family kinases, impacting the JAK/STAT pathway. This indirectly suppresses ZSCAN5B, as JAK/STAT signaling is interlinked with ZSCAN5B regulation. Dasatinib's role in influencing the JAK/STAT pathway thereby translates to a consequential modulation of ZSCAN5B expression. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib targets Bcr-Abl, disrupting the JAK/STAT pathway. The downstream effect on ZSCAN5B is evident through the intricate connection between Bcr-Abl and JAK/STAT signaling. Imatinib’s selectivity in blocking Bcr-Abl ensures a specific impact on the pathway, subsequently influencing ZSCAN5B modulation. | ||||||
Saracatinib | 379231-04-6 | sc-364607 sc-364607A | 10 mg 200 mg | $115.00 $1056.00 | 7 | |
Saracatinib inhibits Src kinases, affecting the PI3K/Akt pathway. ZSCAN5B, a downstream target of PI3K/Akt, is modulated by Saracatinib through its interference with Src kinases. The specificity of Saracatinib in targeting Src kinases ensures precise control over the PI3K/Akt pathway and subsequent ZSCAN5B modulation. | ||||||
Sotrastaurin | 425637-18-9 | sc-474229 sc-474229A | 5 mg 10 mg | $300.00 $540.00 | ||
Sotrastaurin is a PKC inhibitor, disrupting the NF-κB pathway. ZSCAN5B, a downstream effector of NF-κB, is modulated by Sotrastaurin's impact on PKC. This compound specifically targets PKC, ensuring a selective influence on the NF-κB pathway, leading to consequential modulation of ZSCAN5B expression. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib inhibits RAF kinases, disrupting the MAPK pathway. ZSCAN5B, downstream of MAPK, is modulated as Sorafenib alters the phosphorylation cascade within the pathway. Sorafenib’s specificity in targeting RAF kinases ensures selective modulation of the MAPK pathway, leading to subsequent modulation of ZSCAN5B. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
AZD5363 is a selective inhibitor of AKT, impacting the PI3K/Akt pathway. ZSCAN5B, downstream of PI3K/Akt, is modulated by AZD5363 through its interference with AKT. The specificity of AZD5363 in targeting AKT ensures precise control over the PI3K/Akt pathway, leading to subsequent modulation of ZSCAN5B. | ||||||